Drug Trial Radar · NCT06134362
Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
2,998
Actual
Start
May 14, 2024
Primary completion
Mar 14, 2029
Study completion Mar 14, 2029
Sponsor
- Lead sponsor
- ViiV HealthcareGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- GlaxoSmithKline; PPD Development, LP
- First posted
- Nov 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is long-term evaluation of long-acting injectable cabotegravir (CAB LA) for HIV pre-exposure prophylaxis (PrEP) in eligible participants who have completed DAIDS (Division of AIDS) sponsored studies HPTN 083 and HPTN 084 and associated sub-studies. Participants will continue receiving CAB LA and be followed for new HIV diagnosis, SAEs (serious adverse events), Grade 3 and Grade 4 ISRs (injection site reactions), and AEs (adverse events) leading to withdrawal.
Conditions
- HIV Infections
Interventions
CAB LADrug
Participants will receive CAB LA 600 mg via gluteal IM injection, once every 8 weeks (Q8W).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with new HIV infectionTime frame: From Day 1 up to end of study (up to approximately [approx.] 3 years)
- Number of participants with new HIV infection by characteristicTime frame: From Day 1 up to end of study (up to approx. 3 years)
Locations
33 sites in 12 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Almagro, Argentina
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Francistown, Botswana
GSK Investigational Site
Rio de Janeiro, Brazil
GSK Investigational Site
São Paulo, Brazil
GSK Investigational Site
São Paulo, Brazil
GSK Investigational Site
Porto Alegre, Rio Grande do Sul, Brazil
GSK Investigational Site
Mbabane, Eswatini
GSK Investigational Site
Kisumu, Kenya
GSK Investigational Site
Blantyre, Malawi
GSK Investigational Site
Lilongwe, Malawi
GSK Investigational Site
Lima, Peru
GSK Investigational Site
Lima, Peru
GSK Investigational Site
Lima, Peru
GSK Investigational Site
Lima, Peru
GSK Investigational Site
Piura, Peru
GSK Investigational Site
Cape Town, South Africa
GSK Investigational Site
City of Cape Town, South Africa
GSK Investigational Site
City of Cape Town, South Africa
GSK Investigational Site
City of Johannesburg, South Africa
GSK Investigational Site
Durban, South Africa
GSK Investigational Site
Durban, South Africa
GSK Investigational Site
Isipingo, South Africa
GSK Investigational Site
Sol Plaatjie, South Africa
GSK Investigational Site
Pathum Wan, Thailand
GSK Investigational Site
Chiang Mai, Chiang Mai, Thailand
GSK Investigational Site
Entebbe, Uganda
GSK Investigational Site
Kampala, Uganda
GSK Investigational Site
Hanoi, Vietnam
GSK Investigational Site
Chitungwiza, Zimbabwe
GSK Investigational Site
Chitungwiza, Zimbabwe
GSK Investigational Site
Chitungwiza, Zimbabwe
GSK Investigational Site
Harare, Zimbabwe
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.